Insys Therapeutics (NASDAQ: INSY) reported Q3 EPS of $0.50, $0.27 better than the analyst estimate of $0.23. Revenue for the quarter came in at $91.3 million versus the consensus estimate of $82.98 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.